Berobenatide
CLevel 1 evidenceBerobenatide
Basic Information
GLP-1 receptor agonist
Pfizer's ultra-long-acting, fully biased GLP-1RA is designed for once-monthly injection, achieving 15.9% weight loss in the Phase IIb trial at week 60.
Efficacy Rating
Class C
No data available
No data available
China Regulatory Status
No data available
No data available
No data available
Similar Peptide Recommendations
ASC30
ASC30
Research, GLP-1, small molecules
Avexitide
Avexitide
Research, GLP-1 antagonists, hypoglycemia
DA-1726
DA-1726
Research, Weight Loss, GLP-1
Imapextide
Imapextide
Research: GLP-1 Antagonists and Post-Bariatric Hypoglycemia
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.